We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan has agreed to shed two generics that treat muscle pain and epilepsy to allay FTC antitrust concerns, clearing the way for its $7.2 billion acquisition of Meda. Read More
The EMA is advising drugmakers to rely on two types of analyses — metabolic and mechanism of action — to determine the minimum effective dosage for antimicrobial drugs. Read More
An anticipated uptick in generic drug submissions is leading the FDA to lower its fees for approval applications and supplemental filings next fiscal year. Read More
Another online supplement distributor has earned the FDA’s ire for selling weight-loss supplements that contain undisclosed prescription ingredients and potentially carcinogenic ingredients. Read More